NCT04076540View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

January 2, 2022

Study Completion Date

January 2, 2022

Conditions

Smoking Cessation

Interventions

DRUG

AZD4041

Administration by Oral syringe

DRUG

Placebo

Administration by Oral syringe

Trial Locations (2)

78744

Research Site, Austin

89113

Research Site, Las Vegas

Sponsors

Lead Sponsor

Collaborators (1)

Eolas Therapeutics INC.

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Eolas Therapeutics INC.

INDUSTRY

lead

AstraZeneca

INDUSTRY